[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fH6f4Cb3QslgDll6r9rGpwh0vRJlKGF7Qw7_QHdhVVuA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":30,"phaseBuckets":46,"rows":53},"Seoul St. Mary's Hospital",[4],74,false,6,3,27282,42,[13,15,17,19,22,24,26,28],{"name":14,"count":9},"Lung Cancer",{"name":16,"count":9},"Chronic Myeloid Leukemia",{"name":18,"count":9},"Cholecystitis, Acute",{"name":20,"count":21},"Oxidative Stress",2,{"name":23,"count":21},"Colorectal Cancer",{"name":25,"count":21},"Myelodysplastic Syndrome",{"name":27,"count":21},"Thyroid Cancer",{"name":29,"count":21},"Chronic Myelocytic Leukemia",[31,36,41],{"nctId":32,"briefTitle":33,"date":34,"intervention":35},"NCT07380867","Confirming the Accuracy of Endoscopic Marking Using a New Marker, a Novel Luminomarker, in Lesion Marking Before Colorectal Cancer Surgery.","2026-12-31","LuminoMark inj. 0.2mL",{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT07240844","Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy","2027-04-29","Enavogliflozin 0.3mg",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04942886","Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation","2028-12-31","Baracle Tab.®",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,79,104,126,155,173,191,219,237,255,282,300,327,352,376,401,427,452,470,496,520,546,564,582,616,641,667,685,709,736,754,778,806,832,850,874,901,927,952,970,993,1018,1043],{"intervention":40,"totalTrials":55,"cells":56},1,{"EARLY_PHASE1":57,"PHASE1":60,"PHASE2":62,"PHASE3":64,"PHASE4":66,"NA":77},{"trials":58,"activeCount":59},[],0,{"trials":61,"activeCount":59},[],{"trials":63,"activeCount":59},[],{"trials":65,"activeCount":59},[],{"trials":67,"activeCount":55,"soonestReadout":39},[68],{"nctId":37,"briefTitle":38,"status":69,"phases":70,"primaryCompletion":39,"completion":71,"start":72,"enrollment":73,"conditions":74,"interventions":76},"NOT_YET_RECRUITING",[51],"2027-05-31","2025-11-24",68,[75],"Amyloid Cardiomyopathy",[40],{"trials":78,"activeCount":59},[],{"intervention":45,"totalTrials":55,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":87,"PHASE4":89,"NA":91},{"trials":82,"activeCount":59},[],{"trials":84,"activeCount":59},[],{"trials":86,"activeCount":59},[],{"trials":88,"activeCount":59},[],{"trials":90,"activeCount":59},[],{"trials":92,"activeCount":55,"soonestReadout":44},[93],{"nctId":42,"briefTitle":43,"status":94,"phases":95,"primaryCompletion":44,"completion":44,"start":96,"enrollment":97,"conditions":98,"interventions":103},"ENROLLING_BY_INVITATION",[52],"2021-08-21",226,[99,100,101,102],"Hepatitis B Reactivation","Hematopoietic Stem Cell Transplantation","Antiviral Drug","HBV",[45],{"intervention":35,"totalTrials":55,"cells":105},{"EARLY_PHASE1":106,"PHASE1":108,"PHASE2":110,"PHASE3":112,"PHASE4":114,"NA":116},{"trials":107,"activeCount":59},[],{"trials":109,"activeCount":59},[],{"trials":111,"activeCount":59},[],{"trials":113,"activeCount":59},[],{"trials":115,"activeCount":59},[],{"trials":117,"activeCount":55,"soonestReadout":34},[118],{"nctId":32,"briefTitle":33,"status":94,"phases":119,"primaryCompletion":34,"completion":34,"start":120,"enrollment":121,"conditions":122,"interventions":125},[52],"2025-12-22",30,[23,123,124],"Endoscopic Tattoo of Suspected Colon Cancer","Indocyanine Green (ICG)",[35],{"intervention":127,"totalTrials":55,"cells":128},"Rosiglitazone",{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":153},{"trials":130,"activeCount":59},[],{"trials":132,"activeCount":59},[],{"trials":134,"activeCount":59},[],{"trials":136,"activeCount":59},[],{"trials":138,"activeCount":59},[139],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},"NCT01406704","Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH","TERMINATED",[51],"2010-12","2013-12","2004-01",26,[149],"NASH (Non-alcoholic Steato-hepatitis)",[127,151,152],"alpha-lipoic acid","Rosiglitazone\u002Falpha-lipoic acid",{"trials":154,"activeCount":59},[],{"intervention":151,"totalTrials":55,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":171},{"trials":158,"activeCount":59},[],{"trials":160,"activeCount":59},[],{"trials":162,"activeCount":59},[],{"trials":164,"activeCount":59},[],{"trials":166,"activeCount":59},[167],{"nctId":140,"briefTitle":141,"status":142,"phases":168,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":169,"interventions":170},[51],[149],[127,151,152],{"trials":172,"activeCount":59},[],{"intervention":152,"totalTrials":55,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":189},{"trials":176,"activeCount":59},[],{"trials":178,"activeCount":59},[],{"trials":180,"activeCount":59},[],{"trials":182,"activeCount":59},[],{"trials":184,"activeCount":59},[185],{"nctId":140,"briefTitle":141,"status":142,"phases":186,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":187,"interventions":188},[51],[149],[127,151,152],{"trials":190,"activeCount":59},[],{"intervention":192,"totalTrials":55,"cells":193},"Everolimus",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":202,"NA":217},{"trials":195,"activeCount":59},[],{"trials":197,"activeCount":59},[],{"trials":199,"activeCount":59},[],{"trials":201,"activeCount":59},[],{"trials":203,"activeCount":59},[204],{"nctId":205,"briefTitle":206,"status":207,"phases":208,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT02036554","Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients","UNKNOWN",[51],"2015-12","2013-03",234,[213],"Kidney; Complications, Allograft",[192,215,216],"Tacrolimus","Mycophenolic acid",{"trials":218,"activeCount":59},[],{"intervention":215,"totalTrials":55,"cells":220},{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":229,"NA":235},{"trials":222,"activeCount":59},[],{"trials":224,"activeCount":59},[],{"trials":226,"activeCount":59},[],{"trials":228,"activeCount":59},[],{"trials":230,"activeCount":59},[231],{"nctId":205,"briefTitle":206,"status":207,"phases":232,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":233,"interventions":234},[51],[213],[192,215,216],{"trials":236,"activeCount":59},[],{"intervention":216,"totalTrials":55,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":253},{"trials":240,"activeCount":59},[],{"trials":242,"activeCount":59},[],{"trials":244,"activeCount":59},[],{"trials":246,"activeCount":59},[],{"trials":248,"activeCount":59},[249],{"nctId":205,"briefTitle":206,"status":207,"phases":250,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":251,"interventions":252},[51],[213],[192,215,216],{"trials":254,"activeCount":59},[],{"intervention":256,"totalTrials":55,"cells":257},"Closone",{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":266,"NA":280},{"trials":259,"activeCount":59},[],{"trials":261,"activeCount":59},[],{"trials":263,"activeCount":59},[],{"trials":265,"activeCount":59},[],{"trials":267,"activeCount":59},[268],{"nctId":269,"briefTitle":270,"status":271,"phases":272,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":278},"NCT01763749","Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin","COMPLETED",[51],"2014-10","2012-10",91,[277],"Coronary Artery Disease",[256,279],"Plavix with Astrix",{"trials":281,"activeCount":59},[],{"intervention":279,"totalTrials":55,"cells":283},{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":292,"NA":298},{"trials":285,"activeCount":59},[],{"trials":287,"activeCount":59},[],{"trials":289,"activeCount":59},[],{"trials":291,"activeCount":59},[],{"trials":293,"activeCount":59},[294],{"nctId":269,"briefTitle":270,"status":271,"phases":295,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":296,"interventions":297},[51],[277],[256,279],{"trials":299,"activeCount":59},[],{"intervention":301,"totalTrials":55,"cells":302},"Rocuronium",{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":325},{"trials":304,"activeCount":59},[],{"trials":306,"activeCount":59},[],{"trials":308,"activeCount":59},[],{"trials":310,"activeCount":59},[],{"trials":312,"activeCount":59},[313],{"nctId":314,"briefTitle":315,"status":271,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":324},"NCT02185339","Effects of Deep Neuromuscular Blockade on Intraoperative Respiratory Mechanics",[51],"2015-01","2014-07",61,[321,322,323],"Laparoscopic Renal Surgery","Laparoscopy","Muscle Relaxation",[301,301],{"trials":326,"activeCount":59},[],{"intervention":328,"totalTrials":55,"cells":329},"G-CSF",{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":348,"NA":350},{"trials":331,"activeCount":59},[],{"trials":333,"activeCount":59},[],{"trials":335,"activeCount":59},[],{"trials":337,"activeCount":59},[338],{"nctId":339,"briefTitle":340,"status":207,"phases":341,"primaryCompletion":342,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},"NCT02427919","Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML",[49,50],"2017-12","2015-03",56,[346],"Leukemia, Myeloid, Acute",[328],{"trials":349,"activeCount":59},[],{"trials":351,"activeCount":59},[],{"intervention":353,"totalTrials":55,"cells":354},"Nilotinib, Imatinib",{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":361,"PHASE4":372,"NA":374},{"trials":356,"activeCount":59},[],{"trials":358,"activeCount":59},[],{"trials":360,"activeCount":59},[],{"trials":362,"activeCount":59},[363],{"nctId":364,"briefTitle":365,"status":207,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":371},"NCT01400074","Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib",[50],"2014-06","2009-01",100,[16],[353],{"trials":373,"activeCount":59},[],{"trials":375,"activeCount":59},[],{"intervention":377,"totalTrials":55,"cells":378},"Azacitidine",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":395,"PHASE4":397,"NA":399},{"trials":380,"activeCount":59},[],{"trials":382,"activeCount":59},[],{"trials":384,"activeCount":59},[385],{"nctId":386,"briefTitle":387,"status":207,"phases":388,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":394},"NCT01652781","5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome",[49],"2016-06","2016-12","2012-03",92,[25],[377],{"trials":396,"activeCount":59},[],{"trials":398,"activeCount":59},[],{"trials":400,"activeCount":59},[],{"intervention":402,"totalTrials":55,"cells":403},"Paclitaxel",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":405,"activeCount":59},[],{"trials":407,"activeCount":59},[],{"trials":409,"activeCount":59},[410],{"nctId":411,"briefTitle":412,"status":207,"phases":413,"primaryCompletion":414,"completion":415,"start":416,"enrollment":319,"conditions":417,"interventions":420},"NCT04943653","Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis",[48,49],"2023-12","2025-12","2021-06-08",[418,402,419],"Stomach Neoplasms","Peritoneal Metastases",[402],{"trials":422,"activeCount":59},[],{"trials":424,"activeCount":59},[],{"trials":426,"activeCount":59},[],{"intervention":428,"totalTrials":55,"cells":429},"Human Serum Albumin 20",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":446,"PHASE4":448,"NA":450},{"trials":431,"activeCount":59},[],{"trials":433,"activeCount":59},[],{"trials":435,"activeCount":59},[436],{"nctId":437,"briefTitle":438,"status":142,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":21,"conditions":442,"interventions":444},"NCT01684462","The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke",[49],"2014-09","2012-09",[443],"Cerebral Infarction",[428,445],"0.9 % Normal Saline",{"trials":447,"activeCount":59},[],{"trials":449,"activeCount":59},[],{"trials":451,"activeCount":59},[],{"intervention":445,"totalTrials":55,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":464,"PHASE4":466,"NA":468},{"trials":455,"activeCount":59},[],{"trials":457,"activeCount":59},[],{"trials":459,"activeCount":59},[460],{"nctId":437,"briefTitle":438,"status":142,"phases":461,"primaryCompletion":440,"completion":440,"start":441,"enrollment":21,"conditions":462,"interventions":463},[49],[443],[428,445],{"trials":465,"activeCount":59},[],{"trials":467,"activeCount":59},[],{"trials":469,"activeCount":59},[],{"intervention":471,"totalTrials":55,"cells":472},"Catholic MASTER cell",{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":474,"activeCount":59},[],{"trials":476,"activeCount":59},[],{"trials":478,"activeCount":59},[479],{"nctId":480,"briefTitle":481,"status":207,"phases":482,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":489},"NCT04240873","Clinical Study of Intra Articular Injection of Catholic MASTER Cell (Bone Marrow Derived Mesenchymal Stem Cell) in Knee Osteoarthritis",[48,49],"2021-03-31","2022-03-31","2019-11-15",24,[488],"Osteoarthritis, Knee",[471],{"trials":491,"activeCount":59},[],{"trials":493,"activeCount":59},[],{"trials":495,"activeCount":59},[],{"intervention":497,"totalTrials":55,"cells":498},"Decitabine",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":512,"PHASE3":514,"PHASE4":516,"NA":518},{"trials":500,"activeCount":59},[],{"trials":502,"activeCount":59},[503],{"nctId":504,"briefTitle":505,"status":207,"phases":506,"primaryCompletion":440,"completion":209,"start":507,"enrollment":508,"conditions":509,"interventions":511},"NCT01277484","Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS\u002FAML",[48],"2011-01",19,[25,510],"Acute Myeloid Leukemia",[497],{"trials":513,"activeCount":59},[],{"trials":515,"activeCount":59},[],{"trials":517,"activeCount":59},[],{"trials":519,"activeCount":59},[],{"intervention":521,"totalTrials":55,"cells":522},"Baraclude Tab. 0.5mg, fasting",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":544},{"trials":524,"activeCount":59},[],{"trials":526,"activeCount":59},[527],{"nctId":528,"briefTitle":529,"status":207,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":121,"conditions":533,"interventions":535},"NCT02586363","Study of Evaluation of Cavir Tab. 0.5mg With Food Effect on Pharmacokinetics and Safety",[48],"2016-03","2015-11",[534],"Healthy",[521,536,537],"Cavir Tab. 0.5mg, fasting","Cavir Tab. 0.5mg, high fatty meal",{"trials":539,"activeCount":59},[],{"trials":541,"activeCount":59},[],{"trials":543,"activeCount":59},[],{"trials":545,"activeCount":59},[],{"intervention":536,"totalTrials":55,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":549,"activeCount":59},[],{"trials":551,"activeCount":59},[552],{"nctId":528,"briefTitle":529,"status":207,"phases":553,"primaryCompletion":531,"completion":531,"start":532,"enrollment":121,"conditions":554,"interventions":555},[48],[534],[521,536,537],{"trials":557,"activeCount":59},[],{"trials":559,"activeCount":59},[],{"trials":561,"activeCount":59},[],{"trials":563,"activeCount":59},[],{"intervention":537,"totalTrials":55,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":574,"PHASE3":576,"PHASE4":578,"NA":580},{"trials":567,"activeCount":59},[],{"trials":569,"activeCount":59},[570],{"nctId":528,"briefTitle":529,"status":207,"phases":571,"primaryCompletion":531,"completion":531,"start":532,"enrollment":121,"conditions":572,"interventions":573},[48],[534],[521,536,537],{"trials":575,"activeCount":59},[],{"trials":577,"activeCount":59},[],{"trials":579,"activeCount":59},[],{"trials":581,"activeCount":59},[],{"intervention":583,"totalTrials":21,"cells":584},"Immunotherapy",{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":595},{"trials":586,"activeCount":59},[],{"trials":588,"activeCount":59},[],{"trials":590,"activeCount":59},[],{"trials":592,"activeCount":59},[],{"trials":594,"activeCount":59},[],{"trials":596,"activeCount":59},[597,607],{"nctId":598,"briefTitle":599,"status":207,"phases":600,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":606},"NCT06205823","Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM",[],"2025-12-31","2023-09-25",1600,[605],"Myeloma Multiple",[583],{"nctId":608,"briefTitle":609,"status":207,"phases":610,"primaryCompletion":601,"completion":601,"start":611,"enrollment":612,"conditions":613,"interventions":615},"NCT06202885","CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy",[],"2023-10-01",2500,[614],"Lymphoma",[583],{"intervention":617,"totalTrials":55,"cells":618},"Avastin",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":629},{"trials":620,"activeCount":59},[],{"trials":622,"activeCount":59},[],{"trials":624,"activeCount":59},[],{"trials":626,"activeCount":59},[],{"trials":628,"activeCount":59},[],{"trials":630,"activeCount":59},[631],{"nctId":632,"briefTitle":633,"status":207,"phases":634,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":640},"NCT01422018","Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy",[52],"2012-02","2011-08",10,[639],"Diabetes Complications",[617],{"intervention":642,"totalTrials":55,"cells":643},"GX-188E, GX-I7",{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":650,"PHASE4":652,"NA":654},{"trials":645,"activeCount":59},[],{"trials":647,"activeCount":59},[],{"trials":649,"activeCount":59},[],{"trials":651,"activeCount":59},[],{"trials":653,"activeCount":59},[],{"trials":655,"activeCount":59},[656],{"nctId":657,"briefTitle":658,"status":207,"phases":659,"primaryCompletion":660,"completion":660,"start":661,"enrollment":662,"conditions":663,"interventions":665},"NCT03206138","Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.",[52],"2018-10","2017-05-30",50,[664],"Cervical Intraepithelial Neoplasia 3",[642,666],"GX-188E, Imiquimod",{"intervention":666,"totalTrials":55,"cells":668},{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":670,"activeCount":59},[],{"trials":672,"activeCount":59},[],{"trials":674,"activeCount":59},[],{"trials":676,"activeCount":59},[],{"trials":678,"activeCount":59},[],{"trials":680,"activeCount":59},[681],{"nctId":657,"briefTitle":658,"status":207,"phases":682,"primaryCompletion":660,"completion":660,"start":661,"enrollment":662,"conditions":683,"interventions":684},[52],[664],[642,666],{"intervention":686,"totalTrials":55,"cells":687},"Intravitreal Avastin",{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":689,"activeCount":59},[],{"trials":691,"activeCount":59},[],{"trials":693,"activeCount":59},[],{"trials":695,"activeCount":59},[],{"trials":697,"activeCount":59},[],{"trials":699,"activeCount":59},[700],{"nctId":701,"briefTitle":702,"status":207,"phases":703,"primaryCompletion":704,"completion":704,"start":636,"enrollment":705,"conditions":706,"interventions":708},"NCT01439178","Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab",[52],"2011-11",28,[707],"Complications of Diabetes Mellitus",[686],{"intervention":710,"totalTrials":55,"cells":711},"Active fluid management with BIA monitoring",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":722},{"trials":713,"activeCount":59},[],{"trials":715,"activeCount":59},[],{"trials":717,"activeCount":59},[],{"trials":719,"activeCount":59},[],{"trials":721,"activeCount":59},[],{"trials":723,"activeCount":59},[724],{"nctId":725,"briefTitle":726,"status":271,"phases":727,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":734},"NCT06097923","Implementation of Fluid Strategies Using Real-time Bioelectrical Analyzer in Surgical Intensive Care Unit (SICU)",[52],"2022-12-31","2021-11-30",200,[732,733],"Fluid Overload","Fluid Loss",[710,735],"Conventional fluid management without BIA monitoring",{"intervention":735,"totalTrials":55,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":746,"NA":748},{"trials":739,"activeCount":59},[],{"trials":741,"activeCount":59},[],{"trials":743,"activeCount":59},[],{"trials":745,"activeCount":59},[],{"trials":747,"activeCount":59},[],{"trials":749,"activeCount":59},[750],{"nctId":725,"briefTitle":726,"status":271,"phases":751,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":752,"interventions":753},[52],[732,733],[710,735],{"intervention":755,"totalTrials":55,"cells":756},"Nilotinib",{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":758,"activeCount":59},[],{"trials":760,"activeCount":59},[],{"trials":762,"activeCount":59},[],{"trials":764,"activeCount":59},[],{"trials":766,"activeCount":59},[],{"trials":768,"activeCount":59},[769],{"nctId":770,"briefTitle":771,"status":207,"phases":772,"primaryCompletion":367,"completion":773,"start":774,"enrollment":775,"conditions":776,"interventions":777},"NCT01562847","Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib",[],"2015-06","2011-07",125,[16],[755],{"intervention":779,"totalTrials":55,"cells":780},"Dual-antiplatelet therapy",{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":782,"activeCount":59},[],{"trials":784,"activeCount":59},[],{"trials":786,"activeCount":59},[],{"trials":788,"activeCount":59},[],{"trials":790,"activeCount":59},[],{"trials":792,"activeCount":59},[793],{"nctId":794,"briefTitle":795,"status":207,"phases":796,"primaryCompletion":797,"completion":798,"start":146,"enrollment":799,"conditions":800,"interventions":805},"NCT02806102","CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)",[],"2017-02","2018-02",13000,[801,802,803,804],"Acute Myocardial Infarction","Percutaneous Coronary Intervention","Major Adverse Cardiovascular Events","Bleeding",[779,779],{"intervention":807,"totalTrials":55,"cells":808},"The intravenous ferritin group",{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":817,"NA":819},{"trials":810,"activeCount":59},[],{"trials":812,"activeCount":59},[],{"trials":814,"activeCount":59},[],{"trials":816,"activeCount":59},[],{"trials":818,"activeCount":59},[],{"trials":820,"activeCount":59},[821],{"nctId":822,"briefTitle":823,"status":207,"phases":824,"primaryCompletion":825,"completion":601,"start":826,"enrollment":827,"conditions":828,"interventions":830},"NCT06442111","The Role of Intravenous Ferritin in Optimizing Postoperative Recovery Following Pancreaticoduodenectomy",[52],"2025-06-30","2024-07-01",106,[829],"Pancreaticojuodenectomy",[807,831],"The placebo group",{"intervention":831,"totalTrials":55,"cells":833},{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":840,"PHASE4":842,"NA":844},{"trials":835,"activeCount":59},[],{"trials":837,"activeCount":59},[],{"trials":839,"activeCount":59},[],{"trials":841,"activeCount":59},[],{"trials":843,"activeCount":59},[],{"trials":845,"activeCount":59},[846],{"nctId":822,"briefTitle":823,"status":207,"phases":847,"primaryCompletion":825,"completion":601,"start":826,"enrollment":827,"conditions":848,"interventions":849},[52],[829],[807,831],{"intervention":851,"totalTrials":55,"cells":852},"Dexmedetomidine",{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":854,"activeCount":59},[],{"trials":856,"activeCount":59},[],{"trials":858,"activeCount":59},[],{"trials":860,"activeCount":59},[],{"trials":862,"activeCount":59},[],{"trials":864,"activeCount":59},[865],{"nctId":866,"briefTitle":867,"status":271,"phases":868,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":873},"NCT04007341","Effect of Dexmedetomidine on the Inflammatory Response After One-lung Ventilation",[52],"2019-01-18","2018-07-29",40,[14],[851],{"intervention":875,"totalTrials":55,"cells":876},"caffeine citrate",{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":883,"PHASE4":885,"NA":887},{"trials":878,"activeCount":59},[],{"trials":880,"activeCount":59},[],{"trials":882,"activeCount":59},[],{"trials":884,"activeCount":59},[],{"trials":886,"activeCount":59},[],{"trials":888,"activeCount":59},[889],{"nctId":890,"briefTitle":891,"status":271,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":900},"NCT05393817","Caffeine Citrate Use and Electronic Activity of the Diaphragm (EDI) Changes",[],"2023-10-18","2022-06-08",14,[897,898,899],"Preterm","Apnea of Prematurity","Caffeine",[875],{"intervention":902,"totalTrials":55,"cells":903},"Gilotrif",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":914},{"trials":905,"activeCount":59},[],{"trials":907,"activeCount":59},[],{"trials":909,"activeCount":59},[],{"trials":911,"activeCount":59},[],{"trials":913,"activeCount":59},[],{"trials":915,"activeCount":59},[916],{"nctId":917,"briefTitle":918,"status":207,"phases":919,"primaryCompletion":920,"completion":921,"start":922,"enrollment":923,"conditions":924,"interventions":926},"NCT04930133","Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy",[],"2020-12-17","2021-09-30","2020-02-24",737,[925],"NSCLC",[902],{"intervention":928,"totalTrials":55,"cells":929},"Inhaled iloprost",{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":938,"NA":940},{"trials":931,"activeCount":59},[],{"trials":933,"activeCount":59},[],{"trials":935,"activeCount":59},[],{"trials":937,"activeCount":59},[],{"trials":939,"activeCount":59},[],{"trials":941,"activeCount":59},[942],{"nctId":943,"briefTitle":944,"status":271,"phases":945,"primaryCompletion":946,"completion":946,"start":947,"enrollment":948,"conditions":949,"interventions":950},"NCT03936140","The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery",[52],"2018-10-24","2018-01-04",72,[14],[928,951],"Distilled water",{"intervention":951,"totalTrials":55,"cells":953},{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":964},{"trials":955,"activeCount":59},[],{"trials":957,"activeCount":59},[],{"trials":959,"activeCount":59},[],{"trials":961,"activeCount":59},[],{"trials":963,"activeCount":59},[],{"trials":965,"activeCount":59},[966],{"nctId":943,"briefTitle":944,"status":271,"phases":967,"primaryCompletion":946,"completion":946,"start":947,"enrollment":948,"conditions":968,"interventions":969},[52],[14],[928,951],{"intervention":971,"totalTrials":55,"cells":972},"salvage chemotherapy, total body irradiation",{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":974,"activeCount":59},[],{"trials":976,"activeCount":59},[],{"trials":978,"activeCount":59},[],{"trials":980,"activeCount":59},[],{"trials":982,"activeCount":59},[],{"trials":984,"activeCount":59},[985],{"nctId":986,"briefTitle":987,"status":207,"phases":988,"primaryCompletion":209,"completion":209,"start":989,"enrollment":369,"conditions":990,"interventions":992},"NCT02044185","Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation",[],"2014-01",[991],"Acute Graft-versus-host Disease",[971],{"intervention":994,"totalTrials":55,"cells":995},"Antithyroid Drug",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1006},{"trials":997,"activeCount":59},[],{"trials":999,"activeCount":59},[],{"trials":1001,"activeCount":59},[],{"trials":1003,"activeCount":59},[],{"trials":1005,"activeCount":59},[],{"trials":1007,"activeCount":59},[1008],{"nctId":1009,"briefTitle":1010,"status":271,"phases":1011,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1015,"interventions":1017},"NCT04383795","Change of Gut Microbiome in the Treatment of Graves' Disease",[],"2021-12-31","2020-05-19",29,[1016],"Graves' Disease",[994],{"intervention":1019,"totalTrials":55,"cells":1020},"ranibizumab",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1029,"NA":1031},{"trials":1022,"activeCount":59},[],{"trials":1024,"activeCount":59},[],{"trials":1026,"activeCount":59},[],{"trials":1028,"activeCount":59},[],{"trials":1030,"activeCount":59},[],{"trials":1032,"activeCount":59},[1033],{"nctId":1034,"briefTitle":1035,"status":207,"phases":1036,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":1039,"conditions":1040,"interventions":1042},"NCT01360151","Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy",[52],"2011-05","2011-02",16,[1041],"Polypoidal Choroidal Vasculopathy",[1019],{"intervention":1044,"totalTrials":55,"cells":1045},"Sirolimus",{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1052,"PHASE4":1054,"NA":1056},{"trials":1047,"activeCount":59},[],{"trials":1049,"activeCount":59},[],{"trials":1051,"activeCount":59},[],{"trials":1053,"activeCount":59},[],{"trials":1055,"activeCount":59},[],{"trials":1057,"activeCount":59},[1058],{"nctId":1059,"briefTitle":1060,"status":207,"phases":1061,"primaryCompletion":145,"completion":145,"start":1062,"enrollment":662,"conditions":1063,"interventions":1065},"NCT01592253","Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient",[52],"2012-05",[1064],"Acute Rejection of Renal Transplant",[1044]]